Deutsche Bank Names Top Healthcare Stocks Led by DexCom and Insulet

Deutsche Bank initiated Buy ratings on DexCom at $86, Insulet at $190, and Smurfit Westrock at $57, while starting Tandem Diabetes Care at Hold with a $15.50 target. The note is constructive on diabetes management and packaging, citing improving fundamentals, attractive valuations, and margin or execution improvements, though Tandem’s near-term upside is limited by reimbursement transition risk. Separately, Smurfit Westrock reported Q1 2026 EPS of $0.33, below estimates, on revenue of $7.71 billion versus expectations, and completed its London delisting.

Analysis

The real signal here is not just a favorable read-through on diabetes devices, but a re-rating of duration in a subgroup the market had been treating as structurally threatened by GLP-1 adoption. The key second-order effect is that reimbursement expansion and longer-sensor economics can offset the perceived demand drag from obesity drugs, which means the market may have been over-discounting a terminal-growth problem where the more relevant variable is mix and recurring consumables penetration. That dynamic favors the highest-quality platform with the strongest brand and payer relationships, while leaving lower-margin peers more exposed to any slowdown in procedure-driven account growth.

Insulet looks best positioned tactically because tubeless form factor creates switching friction and supports premium pricing even if growth normalizes. The Moody’s action matters less for near-term cash flow than for how it may constrain narrative multiple expansion if product reliability questions persist into the next 1-2 quarters. Tandem is the opposite setup: improved operating leverage helps, but any reimbursement transition tends to compress visibility before it improves it, so the stock remains vulnerable to a cleaner balance-sheet/quality trade elsewhere in the group.

The packaging call is more interesting as a cyclical-operating leverage story than as a pure valuation idea. If management can transplant a higher-discipline operating model onto a larger North American base, the market may be underestimating margin expansion optionality over 12-24 months, especially if capital returns stay progressive. The risk is that investors are extrapolating synergy capture faster than pricing power and integration execution can support; that gap usually shows up in the first 2-3 quarters after a strategic reset.

Key Decisions for Investors

• Go long DXCM vs. TNDM for a 3-6 month horizon: buy the quality/reimbursement catalyst and short the execution-risk name; target 8-12% relative outperformance if payer adoption continues and margins expand.
• Initiate a tactical long PODD into any post-news weakness over the next 2-4 weeks; use a tight stop below the recent support area because the thesis is multiple re-rating, not a turn in fundamentals.
• Avoid chasing TNDM on strength; if long already, consider trimming on rallies and rotating into DXCM or PODD, since the market is likely to reward clarity over transition stories for the next 1-2 quarters.
• Buy SW on pullbacks as a 12-18 month operational-improvement story; use a 2-3 quarter review point to reassess whether margin progress is translating into estimate revisions and dividend support.
• For a pair trade, long SW / short a lower-quality packaging peer or industrial cyclicals tied to weaker pricing power; the trade works if management execution, not macro, becomes the driver of returns.